한국어
Quantus

Abbott Laboratories

ABT-US · New York Stock Exchange
$116.67+0.03%
2026-08-24 close

Abbott Laboratories — pricey right now, or cheap? And what signals are flashing today?

The grade and valuation bands are below — free to read.

Loading chart…
CloseMA20MA60MA120
2 gurus reporting 13F holdings — Bridgewater (founded by Ray Dalio), Soros Fund (founded by George Soros)
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
Yes · score 0.69
Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

New high + volume — the real recordrecord · not a prediction

Not this one stock, but every new-high-plus-volume pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)

Last 30 sessions
257 picks
Next-day win rate
41%
Avg next-day
-0.41%
vs market
-0.58%p

Beat the market on 40.6% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
08-21 42.9%08-20 57.1%08-19 11.1%08-18 75%08-17 50%08-14 66.7%08-13 16.7%08-12 25%08-11 45.5%08-10 23.1%08-07 54.5%08-06 46.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Trade plan

Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.

Valuation Grades

Relative to 752 건강관리 peers · not investment advice

C+
Overall: 건강관리 477/752 · top 63%
Factor composite · relative position in sector

Valuation in its own history

PER 15.42 · PBR 4.34 — own history (2000-01~) percentiles 85/100 · 65/100

PER85/100
PBR65/100

Higher indicates lower valuation relative to its history (based on earnings and book yields).

Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart1973: $0.004119731974: $0.00451975: $0.00511976: $0.0061977: $0.00771978: $0.01011979: $0.01341980: $0.016119801981: $0.01931982: $0.02271983: $0.02691984: $0.03221985: $0.037819851986: $0.0451987: $0.05371988: $0.06431989: $0.07551990: $0.090119901991: $0.10741992: $0.12921993: $0.14771994: $0.16561995: $0.183519951996: $0.20811997: $0.23491998: $0.26181999: $0.29532000: $0.331120002001: $0.36692002: $0.40952003: $0.43412004: $0.47482005: $0.519120052006: $0.5552007: $0.60772008: $0.67232009: $0.74642010: $0.82320102011: $0.89952012: $0.96172013: $0.562014: $0.882015: $0.9620152016: $1.042017: $1.062018: $1.122019: $1.282020: $1.4420202021: $1.802022: $1.882023: $2.042024: $2.202025: $2.36$2.362025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
A+
Growth
B+
Yield
B-
Safety
A
Reference indicatorView observed cut rates

Paid 53 consecutive years · Raised 12 consecutive years · Yield 2.02% (based on 2025 payment of $2.36) · 3-year growth +7.9%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 4.69
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
4.69
Beneish M-Score
-2.10

No statistical flag

Sloan accrual
5.95%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

7/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score7/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 113% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-08-25

건강관리

This stock is in 건강관리: revenue rank 14 of 547, share 1.6%.

14 / 5471.6%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6Abbott Laboratories1.6%

Concentration

DistributedCR3 37.1%
HHI 642547 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
21

Value lens

P90/P10
23.8
Median P/B
3.04
Level
넓음
n
465

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
15.8%
Interest coverage
11.9x
Return on equity (ROE)
28.1%

Operating margin −5pp

Tolerable
Interest coverageBase 11.9x adverse case 8.1x
Return on equity (ROE)Base 28.1% adverse case 8.4%

Revenue −15%

Tolerable
Interest coverageBase 11.9x adverse case 10.1x
Return on equity (ROE)Base 28.1% adverse case 10.7%

Interest rate +2pp

Tolerable
Interest coverageBase 11.9x adverse case 5.4x
Return on equity (ROE)Base 28.1% adverse case 11.3%

Interest coverage limit

Current margin 14.5pp

Interest coverage limit at an operating margin of 1.3%

Interest expense coverage threshold

Financials at a glance

Abbott Laboratories's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

Curated gurus reporting this holding

A curated subset of well-known investors — not the full institutional ownership.

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ $7.5B(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

New MA alignment×1
26-08-20·

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy